KR101808903B1 - Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신 - Google Patents

Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신 Download PDF

Info

Publication number
KR101808903B1
KR101808903B1 KR1020147030871A KR20147030871A KR101808903B1 KR 101808903 B1 KR101808903 B1 KR 101808903B1 KR 1020147030871 A KR1020147030871 A KR 1020147030871A KR 20147030871 A KR20147030871 A KR 20147030871A KR 101808903 B1 KR101808903 B1 KR 101808903B1
Authority
KR
South Korea
Prior art keywords
mycoplasma
antigen
pcv2
lys
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147030871A
Other languages
English (en)
Korean (ko)
Other versions
KR20150002748A (ko
Inventor
그레고리 피 니첼
제프리 이 갈빈
존 케이트 가렛
제임스 알 세컨드 쿨라윅
트레이시 엘 릭커
메간 마리 스무처
Original Assignee
조에티스 서비시즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48140160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101808903(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 조에티스 서비시즈 엘엘씨 filed Critical 조에티스 서비시즈 엘엘씨
Publication of KR20150002748A publication Critical patent/KR20150002748A/ko
Application granted granted Critical
Publication of KR101808903B1 publication Critical patent/KR101808903B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020147030871A 2012-04-04 2013-04-03 Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신 Active KR101808903B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261620189P 2012-04-04 2012-04-04
US61/620,189 2012-04-04
PCT/US2013/035091 WO2013152086A1 (en) 2012-04-04 2013-04-03 Pcv/mycoplasma hyopneumoniae/prrs combination vaccine

Publications (2)

Publication Number Publication Date
KR20150002748A KR20150002748A (ko) 2015-01-07
KR101808903B1 true KR101808903B1 (ko) 2017-12-13

Family

ID=48140160

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147030871A Active KR101808903B1 (ko) 2012-04-04 2013-04-03 Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신

Country Status (32)

Country Link
US (2) US9125886B2 (https=)
EP (2) EP2833909B1 (https=)
JP (1) JP6271504B2 (https=)
KR (1) KR101808903B1 (https=)
AR (1) AR090614A1 (https=)
AU (1) AU2013243540C1 (https=)
BR (1) BR112014024775B1 (https=)
CA (1) CA2869601C (https=)
CL (1) CL2014002676A1 (https=)
CO (1) CO7160027A2 (https=)
CR (1) CR20140438A (https=)
CY (1) CY1121578T1 (https=)
DK (1) DK2833909T3 (https=)
ES (1) ES2719483T3 (https=)
GT (1) GT201400212A (https=)
HR (2) HRP20140956A2 (https=)
HU (1) HUE042405T2 (https=)
LT (1) LT2833909T (https=)
MX (2) MX336502B (https=)
MY (1) MY168549A (https=)
NI (1) NI201400118A (https=)
PH (1) PH12014502252B1 (https=)
PL (1) PL2833909T3 (https=)
PT (1) PT2833909T (https=)
RS (1) RS58480B1 (https=)
RU (1) RU2644256C2 (https=)
SI (1) SI2833909T1 (https=)
TR (1) TR201905176T4 (https=)
TW (1) TWI504406B (https=)
UA (1) UA114504C2 (https=)
WO (1) WO2013152086A1 (https=)
ZA (1) ZA201407133B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027873B8 (en) 2001-07-02 2015-11-11 Zoetis Services LLC One dose vaccination with mycoplasma hyopneumoniae
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
MX361273B (es) 2012-12-28 2018-12-03 Boehringer Ingelheim Vetmedica Gmbh Metodo para obtener una vacuna de mycoplasma.
AU2013370982C9 (en) * 2012-12-28 2019-01-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
US9649370B2 (en) 2013-05-08 2017-05-16 Protatek International, Inc. Vaccine for PCV2 and mycoplasma
BR112016010427B1 (pt) * 2013-11-21 2020-06-02 Agricultural Technology Research Institute Composição para prevenir infecção por mycoplasma spp., vetor de expressão, e método para prepararantígeno solúvel
RU2655615C1 (ru) * 2013-12-03 2018-05-29 Интервет Интернэшнл Б.В. Вакцина для свиней против prrs и lawsonia intracellularis
CN105848675A (zh) * 2013-12-03 2016-08-10 英特维特国际股份有限公司 抗猪圆环病毒2型的疫苗
CN104056265B (zh) * 2014-07-11 2016-04-27 江苏南农高科技股份有限公司 猪圆环病毒2型、猪繁殖与呼吸综合征二联疫苗及其制备方法
WO2016038194A1 (en) * 2014-09-12 2016-03-17 Intervet International B.V. Vaccine for use in protecting a pig against porcine endemic diarrhea virus
CN107073102B (zh) * 2014-09-12 2021-06-25 英特维特国际股份有限公司 用于保护母猪的后代免于猪流行性腹泻病毒的疫苗
BR112017012220A2 (pt) * 2014-12-11 2018-01-30 Intervet Int Bv processos para preparar uma composição de antígeno e uma vacina, composição de antígeno, vacina, usos de uma composição de antígeno e de uma vacina, e, método para prevenção ou redução de infecção por um vírus em suíno e sinais associados à doença.
JP6839714B2 (ja) * 2015-12-28 2021-03-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド Ｍ Ｈｙｏ多重ワクチン及びその使用
EP3432920A1 (en) 2016-03-23 2019-01-30 Intervet International B.V. A vaccine for intradermal application against pcv2 and prrs virus infection
JP6907227B2 (ja) * 2016-03-23 2021-07-21 インターベット インターナショナル ベー． フェー． Ｐｃｖ２ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン
JP7009445B2 (ja) * 2016-08-09 2022-02-10 アグリカルチュラル テクノロジー リサーチ インスティテュート マイコプラズマ・ヒオリニス感染を予防治療する組成物
MX2019006992A (es) * 2016-12-14 2019-08-29 Zoetis Services Llc Vacunacion eficaz contra cepas europeas del virus del sindrome reproductivo y respiratorio porcino (prrs) previo al destete.
ES2906854T3 (es) * 2016-12-23 2022-04-20 Intervet Int Bv Vacuna combinada para cerdos
US11311614B2 (en) 2017-04-13 2022-04-26 Intervet Inc. Vaccines containing swine pathogens for associated non-mixed use
CN109280642B (zh) * 2017-07-21 2022-07-22 浙江海隆生物科技有限公司 CHO细胞株及其制备方法和使用该CHO细胞株制备猪圆环病毒2型Cap蛋白及其应用
BR112020011044A2 (pt) 2017-12-04 2020-11-17 Intervet International B.V. vacinação com partículas de replicon e adjuvante de óleo
JP7510874B2 (ja) * 2017-12-22 2024-07-04 ヒプラ シエンティフィック エセ．エレ．ウ． マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン
MX420109B (es) 2018-03-26 2025-02-10 Boehringer Ingelheim Animal Health Usa Inc Metodo para producir una composicion inmunogenica
KR102769557B1 (ko) * 2021-11-19 2025-02-20 주식회사 이노백 신규한 재조합 돼지 써코바이러스 2형 단백질 및 이의 용도
CN119913202B (zh) * 2025-01-15 2025-09-19 北京华夏兴洋生物科技有限公司 用于制备猪三联疫苗的重组载体、重组病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
DE3855807T2 (de) 1987-11-03 1997-06-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
ES2112274T5 (es) 1990-05-29 2006-03-01 Wyeth Holdings Corporation Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
JP3128133B2 (ja) 1991-06-06 2001-01-29 スティッチティング セントラール ディールゲネースクンディグ インスティトゥート 豚の奇病の原因体であるレリスタドエイジェント、それを含むワクチン組成物、豚の奇病の診断キット及び診断方法
US5269315A (en) 1991-08-16 1993-12-14 The Regents Of The University Of California Determining the nature of brain lesions by electroencephalography
DK0601062T4 (da) 1991-08-26 2001-03-14 Univ Minnesota SIRS-vaccine og diagnosefremgangsmåde
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
DK0669971T3 (da) 1991-11-15 2003-04-22 Pfizer Fremgangsmåde til fremstilling af Gram-negative bakterielle vacciner
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
PT968722E (pt) 1994-05-10 2007-09-06 Wyeth Corp Vacina viva melhorada contra brsv.
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
KR100615109B1 (ko) 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
AU1535299A (en) 1997-11-26 1999-06-15 Iowa State University Research Foundation Inc. Recombinant (mycoplasma hyopneumoniae) vaccine
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
CA2290220C (en) 1998-12-22 2013-11-19 Pfizer Products Inc. An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
CN1612749A (zh) * 2001-07-02 2005-05-04 辉瑞产品公司 用于减弱牲畜体内牛支原体肺炎的猪肺炎支原体疫苗和方法
EP2027873B8 (en) 2001-07-02 2015-11-11 Zoetis Services LLC One dose vaccination with mycoplasma hyopneumoniae
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
EP1546357B1 (en) 2002-06-28 2013-08-07 Iowa State University Research Foundation, Inc. Immunogenic mycoplasma hyopneumoniae polypeptides
SI1651265T1 (sl) 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
RU2007130801A (ru) 2005-01-13 2009-02-20 Берингер Ингельхайм Ветмедика Гмбх (De) Улучшенные вакцины против репродуктивно-респираторного синдрома свиней (prrs)
ES2425228T3 (es) * 2005-09-09 2013-10-14 Intervet International B.V. Vacuna contra el PCV-2
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
EP3868400A1 (en) 2005-12-29 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
MX2008012972A (es) 2006-04-10 2009-01-16 Intervet Int Bv Vacuna contra sindrome respiratorio reproductivo porcino atenuado vivo de micoplasma.
CN101420975B (zh) * 2006-04-10 2012-06-27 英特威国际有限公司 抗支原体和prrsv的疫苗
EP2217271B1 (en) 2007-11-06 2016-05-04 Zoetis Services LLC Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
KR101320192B1 (ko) 2008-10-16 2013-10-30 조에티스 엘엘씨 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
WO2011141443A1 (en) 2010-05-11 2011-11-17 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
BR112013004594B1 (pt) 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
BR112014022067B1 (pt) 2012-03-07 2022-05-31 Ceva Sante Animale Composição compreendendo antígeno e lipopolissacarídeo
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aust Vet J, Vol 75, Pages 504-511(1997)*

Also Published As

Publication number Publication date
MX354773B (es) 2018-03-20
CO7160027A2 (es) 2015-01-15
AU2013243540A1 (en) 2014-10-09
RU2644256C2 (ru) 2018-02-08
JP6271504B2 (ja) 2018-01-31
HRP20140956A2 (hr) 2015-04-24
EP3508217A1 (en) 2019-07-10
US20150284678A1 (en) 2015-10-08
CA2869601C (en) 2018-06-12
CY1121578T1 (el) 2020-05-29
TW201345548A (zh) 2013-11-16
MX336502B (es) 2016-01-21
JP2015512450A (ja) 2015-04-27
CA2869601A1 (en) 2013-10-10
CL2014002676A1 (es) 2014-12-12
GT201400212A (es) 2015-09-23
ZA201407133B (en) 2017-02-22
TR201905176T4 (tr) 2019-05-21
NI201400118A (es) 2015-03-05
US9125886B2 (en) 2015-09-08
WO2013152086A1 (en) 2013-10-10
RS58480B1 (sr) 2019-04-30
PH12014502252A1 (en) 2014-12-15
AU2013243540B2 (en) 2017-10-19
KR20150002748A (ko) 2015-01-07
CN104271153A (zh) 2015-01-07
MX2014012016A (es) 2014-11-10
TWI504406B (zh) 2015-10-21
AR090614A1 (es) 2014-11-26
EP2833909B1 (en) 2019-02-06
HRP20190466T1 (hr) 2019-05-03
MY168549A (en) 2018-11-12
US20130266603A1 (en) 2013-10-10
ES2719483T3 (es) 2019-07-10
CR20140438A (es) 2014-11-12
BR112014024775B1 (pt) 2021-06-08
DK2833909T3 (en) 2019-04-01
PH12014502252B1 (en) 2014-12-15
HK1207283A1 (en) 2016-01-29
PT2833909T (pt) 2019-05-13
SI2833909T1 (sl) 2019-05-31
US9650601B2 (en) 2017-05-16
EP2833909A1 (en) 2015-02-11
PL2833909T3 (pl) 2019-07-31
UA114504C2 (uk) 2017-06-26
BR112014024775A2 (pt) 2017-07-11
HUE042405T2 (hu) 2019-06-28
RU2014140108A (ru) 2016-06-10
LT2833909T (lt) 2019-04-10
AU2013243540C1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
KR101808903B1 (ko) Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신
KR101747507B1 (ko) 마이코플라즈마 하이요뉴모니아 백신
KR102003620B1 (ko) Pcv/마이코플라즈마 하이요뉴모니아 조합 백신
CN104271153B (zh) Pcv/猪肺炎支原体/prrs组合疫苗
HK40072009A (en) Mycoplasma hyopneumoniae vaccine
HK40010886A (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine
HK40010885A (en) Pcv/mycoplasma hyopneumoniae combination vaccine
HK1206609B (en) Pcv/mycoplasma hyopneumoniae combination vaccine
HK1207283B (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20141103

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160307

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160523

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160523

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161227

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160725

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170427

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20171121

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170627

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170328

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20161227

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160725

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20171207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20171207

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20201005

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20201005

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20210929

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20210929

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20220921

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20220921

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee